摘要：中外新指南均强调综合管理与个体化治疗并重，将T2DM合并ASCVD/ASCVD高风险、CKD、超重/肥胖纳入GLP-1RA强适应证，开启“一线明星”药物新纪元！

·

中外新指南，均强调了一线治疗应首先进行T2DM合并症的评估，根据不同合并症的情况个体化治疗，具体推荐如下：

中外新指南均强调综合管理与个体化治疗并重，将T2DM合并ASCVD/ASCVD高风险、CKD、超重/肥胖纳入GLP-1RA强适应证，开启“一线明星”药物新纪元！

参考文献：

[1]Mosenzon O,et al. Cardiovasc Diabetol. 2021 Jul 27;20(1):154.

[2]中华医学会糖尿病学分会.中华糖尿病杂志,2021,13(4):315-409.

[3]American Diabetes Association Professional Practice Committee. Diabetes Care. 2024;47(Suppl 1):S179-S218.

[4]American Diabetes Association Professional Practice Committee . Diabetes Care. 2025; 48(Suppl.1): S207-S238.

[5]Marso SP, et al. N Engl J Med, 2016, 375(19): 1834‐1844.

[6]American Diabetes Association Professional Practice Committee.Diabetes Care 2025; 48(Suppl. 1): S181–S206.

[7]American Diabetes Association Professional Practice Committee. Diabetes Care 2025; 48(Suppl. 1): S239–S251.

[8]Pratley RE,et al. Lancet Diabetes Endocrinol, 2018, 6(4): 275-286.

[9]Rudofsky G,et al.Diabetes Res Clin Pract. 2021 Aug;178:108931.

[10]Rajamand Ekberg N, et al. Prim Care Diabetes. 2021 Oct;15(5):871-878.

[11]Yale JF, et al. Diabetes Obes Metab. 2021 Oct;23(10):2269-2278.

[12]Holmes P, et al. Diabetes Ther. 2021 Nov;12(11):2891-2905.

[13]Newsome P, et al. Aliment Pharmacol Ther. 2019;50(2):193-203.

[14]Newsome PN, et al. N Engl J Med, 2021, 384(12):1113‐1124.

来源：壹生